Efficacy of Quetiapine in Generalised Social Anxiety Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with the LSAS

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

NCT00606541

Social Anxiety Disorder

TERMINATED EARLY_PHASE1

The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment

NCT00407199

Social Phobia

COMPLETED PHASE4

Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.

NCT00314210

Anxiety Disorders

COMPLETED PHASE3

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

NCT00868374

Major Depressive Disorder Generalized Anxiety Disorder

TERMINATED PHASE3

Quetiapine and the Dopaminergic Epigenetic Control

NCT00370500

Schizophrenia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Social Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

quetiapine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written Confirmed Consent,
* All patients meet the DSM IV criteria for generalized social anxiety disorder,
* A score ≥ 60 on the LSAS,
* male and female aged between 18 and 65 years

Exclusion Criteria

* Presence of any primary axis I diagnosis other than social anxiety disorder according to DSM-IV,
* alcohol and/or substance abuse according to DSM-IV criteria within the last 12 months,
* any personality disorder as the primary diagnosis, with the exception of avoidant personality disorder,
* patients at risk of suicide

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No